This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drusano, G. L.
Right arrow Articles by Stein, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drusano, G. L.
Right arrow Articles by Stein, D. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1998, p. 358-361, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Mathematical Modeling of the Interrelationship of CD4 Lymphocyte Count and Viral Load Changes Induced by the Protease Inhibitor Indinavir

George L. Drusano* and Daniel S. Stein

Departments of Medicine and Pharmacology, Albany Medical College, Albany, New York 12208

Received 16 December 1996/Returned for modification 7 May 1997/Accepted 12 June 1997

While CD4 cell counts are widely used to predict disease progression in human immunodeficiency virus (HIV)-infected patients, they are poorly explanatory of the progression to AIDS or death after the introduction of chemotherapy. Changes in HIV load (as measured by RNA PCR) have been shown to be a much better predictor of the risk of disease progression. Since the interrelationship of these markers is of great clinical interest, we modeled the time-averaged return of CD4 cell count and change in viral load subsequent to therapy with the HIV protease inhibitor indinavir. We found that CD4 cell return was significantly related to both the baseline CD4 count (r2 = 0.86, P < 0.001) and the decline in HIV RNA PCR-determined viral load (also referred to in this work as the HIV RNA PCR decline) (r2 = 0.60, P < 0.01). Simultaneously modeling both influences in a linked nonlinear model (r2 = 0.93, P < 0.001) demonstrated that (i) the starting number of CD4 cells accounted for the majority of the change in CD4 cell return and (ii) the return of CD4 cells attributable to viral load decrease was 50% of maximal with only a decrease of approximately 0.2 log of HIV RNA as modeled from the first 12 weeks of therapy. Much greater viral inhibition beyond that necessary for maximal CD4 cell return is possible. Given that HIV RNA PCR decline is more strongly linked to ultimate clinical course in HIV disease, our findings indicate that CD4 return is potentially misleading as an indicator of antiviral effect, since it is determined more by the starting CD4 value than by viral load decline and since near-maximal changes occur with minimal antiviral effect.

* Corresponding author. Mailing address: Departments of Medicine and Pharmacology, Albany Medical College, 47 New Scotland Ave., A-142, Albany, NY 12208. Phone: (518) 262-6330. Fax: (518) 262-6333. E-mail: GLDrusano{at}aol.com.

Antimicrobial Agents and Chemotherapy, February 1998, p. 358-361, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Graziano, F. M., Kettoola, S. Y., Munshower, J. M., Stapleton, J. T., Towfic, G. J. (2008). Effect of spatial distribution of T-Cells and HIV load on HIV progression. Bioinformatics 24: 855-860 [Abstract] [Full Text]  
  • Sanders, G. D., Bayoumi, A. M., Sundaram, V., Bilir, S. P., Neukermans, C. P., Rydzak, C. E., Douglass, L. R., Lazzeroni, L. C., Holodniy, M., Owens, D. K. (2005). Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy. NEJM 352: 570-585 [Abstract] [Full Text]  
  • Aviles, P., Falcoz, C., Guillen, M. J., San Roman, R., Gomez De Las Heras, F., Gargallo-Viola, D. (2001). Correlation between In Vitro and In Vivo Activities of GM 237354, a New Sordarin Derivative, against Candida albicans in an In Vitro Pharmacokinetic-Pharmacodynamic Model and Influence of Protein Binding. Antimicrob. Agents Chemother. 45: 2746-2754 [Abstract] [Full Text]  
  • Binquet, C., Chene, G., Jacqmin-Gadda, H., Journot, V., Saves, M., Lacoste, D., Dabis, F., and the Groupe d'Epidémiologie Clinique du, (2001). Modeling Changes in CD4-positive T-Lymphocyte Counts after the Start of Highly Active Antiretroviral Therapy and the Relation with Risk of Opportunistic Infections The Aquitaine Cohort, 1996-1997. Am J Epidemiol 153: 386-393 [Abstract] [Full Text]  
  • Ikuta, K., Suzuki, S., Horikoshi, H., Mukai, T., Luftig, R. B. (2000). Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis. Microbiol. Mol. Biol. Rev. 64: 725-745 [Abstract] [Full Text]  
  • Weller, S., Radomski, K. M., Lou, Y., Stein, D. S. (2000). Population Pharmacokinetics and Pharmacodynamic Modeling of Abacavir (1592U89) from a Dose-Ranging, Double-Blind, Randomized Monotherapy Trial with Human Immunodeficiency Virus-Infected Subjects. Antimicrob. Agents Chemother. 44: 2052-2060 [Abstract] [Full Text]  
  • McDowell, J. A., Lou, Y., Symonds, W. S., Stein, D. S. (2000). Multiple-Dose Pharmacokinetics and Pharmacodynamics of Abacavir Alone and in Combination with Zidovudine in Human Immunodeficiency Virus-Infected Adults. Antimicrob. Agents Chemother. 44: 2061-2067 [Abstract] [Full Text]  
  • Mouroux, M., Yvon-Groussin, A., Peytavin, G., Delaugerre, C., Legrand, M., Bossi, P., Do, B., Trylesinski, A., Diquet, B., Dohin, E., Delfraissy, J. F., Katlama, C., Calvez, V., The MIKADO Study Group, (2000). Early Virological Failure in Naive Human Immunodeficiency Virus Patients Receiving Saquinavir (Soft Gel Capsule)-Stavudine-Zalcitabine (MIKADO Trial) Is Not Associated with Mutations Conferring Viral Resistance. J. Clin. Microbiol. 38: 2726-2730 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»